» Articles » PMID: 10812731

Stopping Poliovirus Vaccination After Eradication: Issues and Challenges

Overview
Specialty Public Health
Date 2000 May 17
PMID 10812731
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Since 1988 reported polio cases worldwide have declined by about 85% and the number of known or suspected polioendemic countries has decreased from over 120 to less than 50. With eradication of poliomyelitis approaching, issues potentially affecting when and how vaccination against poliovirus can be stopped become extremely important. Because of the potential risks and benefits inherent in such a decision, the best available science, a risk-benefit analysis, contingency plans, a stock pile of poliovirus vaccines, and the endorsement by the global policy-making committees will all be needed before vaccination can be discontinued. The scientific basis for stopping polio immunization has been reviewed by WHO. This Round Table article summarizes the current state of knowledge, provides an update on the processes and timelines for certification, containment, and stopping vaccination, and highlights some of the unanswered scientific questions that will be addressed by further research. These include whether transmission of vaccine-derived poliovirus strains could be sustained so that poliomyelitis could re-emerge in a future unvaccinated population and whether prolonged excretion of vaccine-derived poliovirus from individuals with immune deficiencies could be a mechanism through which this could occur.

Citing Articles

Poliovirus containment risks and their management.

Tebbens R, Kalkowsa D, Thompson K Future Virol. 2021; 13(9):617-628.

PMID: 33598044 PMC: 7885305. DOI: 10.2217/fvl-2018-0079.


Modelling Risk to US Military Populations from Stopping Blanket Mandatory Polio Vaccination.

Burgess C, Burgess A, McMullen K Comput Math Methods Med. 2017; 2017:7981645.

PMID: 29104608 PMC: 5618742. DOI: 10.1155/2017/7981645.


Vaccine-related poliovirus shedding in trivalent polio vaccine and human immunodeficiency virus status: analysis from under five children.

Hassan J, Wangai L, Borus P, Khayeka-Wandabwa C, Karani L, Kithinji M BMC Res Notes. 2017; 10(1):555.

PMID: 29100529 PMC: 5670520. DOI: 10.1186/s13104-017-2843-y.


Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.

Patel M, Cochi S J Infect Dis. 2017; 216(suppl_1):S1-S8.

PMID: 28838196 PMC: 5853839. DOI: 10.1093/infdis/jix117.


Emergence of vaccine-derived polioviruses, Democratic Republic of Congo, 2004-2011.

Gumede N, Lentsoane O, Burns C, Pallansch M, de Gourville E, Yogolelo R Emerg Infect Dis. 2013; 19(10):1583-9.

PMID: 24047933 PMC: 3810735. DOI: 10.3201/eid1910.130028.